ARTICLE | Strategy
Arresto's development
Arresto to help Gilead build liver, pulmonary, cardio franchises; maybe cancer
January 3, 2011 8:00 AM UTC
Gilead Sciences Inc. almost certainly expected its acquisition of Arresto BioSciences Inc. would complement development of the big biotech's ambrisentan in idiopathic pulmonary fibrosis. But right after the deal was announced last month, ambrisentan failed in a Phase III trial for IPF, meaning Arresto's Phase I AB0024 will be the lead antifibrotic in Gilead's pipeline.
Nevertheless, in the broader scheme of things, Arresto will fit nicely with Gilead's efforts to build franchises in liver, pulmonary and cardiovascular diseases, while potentially giving the company a re-entry into cancer...